Literature DB >> 6638719

An endogenous digoxin-like substance in patients with renal impairment.

S W Graves, B Brown, R Valdes.   

Abstract

Digoxin concentrations were measured in serum samples from 102 patients with renal impairment who were receiving digoxin therapy. Many patients had values that differed widely on several currently available immunoassays, with differences as great as 2.9 ng/mL. In contrast, patients with normal renal function who were receiving digoxin had few discrepant results, with the largest difference being 0.5 ng/mL. We also assayed serum samples from 54 patients with renal impairment not on digoxin therapy and found that more than 60% of these digoxin-free patients had false-positive digoxin values on most assays. Our data suggest that a substance with digoxin-like immunoactivity is present in many patients with renal insufficiency. This substance may seriously compromise the accuracy and interpretation of digoxin concentration measurements.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6638719     DOI: 10.7326/0003-4819-99-5-604

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  25 in total

Review 1.  Endogenous factors with immunological and biological activity similar to cardiac glycosides: biochemical and pathophysiological implications.

Authors:  A Clerico; G Mariani
Journal:  J Endocrinol Invest       Date:  1992-05       Impact factor: 4.256

2.  Interference from digoxin-like immunoreactive substance(s) in commercial digoxin kit assay methods.

Authors:  R G Morris; D B Frewin; N C Saccoia; W L Goldsworthy; W S Jeffries; A J McPhee
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis.

Authors:  John M Hamlyn; Paolo Manunta
Journal:  Adv Chronic Kidney Dis       Date:  2015-05       Impact factor: 3.620

Review 4.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

Review 5.  Digitalis toxicity--turning over a new leaf?

Authors:  S J Bhatia
Journal:  West J Med       Date:  1986-07

6.  Renal disease and digoxin immunoassays.

Authors:  N Capps
Journal:  Br Med J (Clin Res Ed)       Date:  1985-12-07

7.  Renal disease and digoxin immunoassays.

Authors:  J McElnay; P M Hooymans
Journal:  Br Med J (Clin Res Ed)       Date:  1985-11-09

8.  Delayed digoxin toxicity following discontinuance in acute renal failure.

Authors:  A M Ho; I M Fraser; D D Suria
Journal:  Can J Anaesth       Date:  1987-03       Impact factor: 5.063

9.  Digoxin toxicity in a premature infant: treatment with Fab fragments of digoxin-specific antibodies.

Authors:  S Presti; D Friedman; J Saslow; E F Doyle; V P Butler; T W Smith; E Haber
Journal:  Pediatr Cardiol       Date:  1985       Impact factor: 1.655

10.  Elevated endogenous digitalis-like substance in hypertensive diabetic patients with a family history of hypertension.

Authors:  S Okamoto; M Ikeda; T Morise; I Miyamori; R Takeda
Journal:  J Endocrinol Invest       Date:  1991-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.